SATURN: An exploration of the dynamic interaction between IL-17, IL-17 inhibition with (secukinumab) and neutrophils in psoriatic arthritis in vitro and ex vivo with exploratory study on the potential role of Vitamin D
Latest Information Update: 28 Oct 2022
At a glance
- Drugs Secukinumab (Primary) ; Leflunomide; Methotrexate; Sulfasalazine
- Indications Psoriatic arthritis
- Focus Pharmacodynamics
- Acronyms SATURN
- Sponsors Novartis
- 08 Apr 2020 Status changed from active, no longer recruiting to completed.
- 11 Oct 2018 Planned number of patients changed from 20 to 19.
- 11 Oct 2018 Planned End Date changed from 1 Aug 2018 to 1 Nov 2019.